Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Ulcerative Colitis: KOL Insight Update Bulletin [August 2016]

Product Code:
596200705
Publication Date:
August 2016
Format:
PDF
Price:
€1010

Gain new KOL insights on the latest events happening in ulcerative colitis (UC): Topics covered include reactions to Takeda’s analyses involving Entyvio (vedolizumab) trough level measurement; Pfizer’s top-line results from a pivotal Phase III maintenance trial (OCTAVE Sustain) of oral Xeljanz (tofacitinib); as well as opinions on Cellceutix’s brilacidin, a defensin-mimetic antibiotic.

Key Questions Answered in this Update Bulletin:

  • According to KOLs, how important is Entyvio trough level monitoring?
  • Will the launch of biosimilar anti-TNFs impact Entyvio usage?
  • What is the KOL reaction to Xeljanz’s Phase III OCTAVE Sustain data?
  • Are KOLs impressed with Xeljanz’s safety profile?
  • What do KOLs think of Cellceutix’s brilacidin and do they have any concerns regarding this agent?



customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved